Search Results - "Wu, Jenny Qun"

Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays by Boyd, Zachary S, Wu, Qun Jenny, O'Brien, Carol, Spoerke, Jill, Savage, Heidi, Fielder, Paul J, Amler, Lukas, Yan, Yibing, Lackner, Mark R

“…Although breast cancer molecular subtypes have been extensively defined by means of gene expression profiling over the past decade, little is known, at the…”
Get full text

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study by Kater, Arnon P, Wu, Jenny Qun, Kipps, Thomas, Eichhorst, Barbara, Hillmen, Peter, D'Rozario, James, Assouline, Sarit, Owen, Carolyn, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Dubois, Julie, Eldering, Eric, Mellink, Clemens, Van Der Kevie-Kersemaekers, Anne-Marie, Kim, Su Young, Chyla, Brenda, Punnoose, Elizabeth, Bolen, Christopher R, Assaf, Zoe June, Jiang, Yanwen, Wang, Jue, Lefebure, Marcus, Boyer, Michelle, Humphrey, Kathryn, Seymour, John F

“…In previous analyses of the MURANO study, fixed-duration venetoclax plus rituximab (VenR) resulted in improved progression-free survival (PFS) compared with…”
Get full text

Chronic Lymphocytic Leukemia (CLL) Clonal Growth Rate Is Slower Following Venetoclax-Rituximab (VenR): Results from a Minimal Residual Disease (MRD) Model from the Randomized Phase 3 Murano Trial by Kater, Arnon P., Lu, Tong, Langerak, Anton W., Mellink, Clemens, Chyla, Brenda, Wu, Jenny Qun, Boyer, Michelle, Lefebure, Marcus, Jiang, Yanwen, Seymour, John F.

“…Introduction: At a median follow-up of 5 years (cutoff of May 8, 2020), the MURANO trial (NCT02005471) demonstrated deeper responses, including superior rates…”
Get full text

Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx) by Seymour, John F., Wu, Jenny Qun, Popovic, Relja, Eichhorst, Barbara, Hillmen, Peter, Kipps, Thomas J., Langerak, Anton W., Owen, Carolyn, Dubois, Julie, Mellink, Clemens, Van Der Kevie-Kersemaekers, Anne-Marie, Dunbar, Fengjiao, Jiang, Yanwen, Chyla, Brenda, Boyer, Michelle, Thadani-Mulero, Maria, Lefebure, Marcus, Harrup, Rosemary, Kater, Arnon P.

“…Introduction: In the MURANO trial (NCT02005471), fixed-duration VenR (2 yrs Ven + R for the first 6 mo) improved survival and rates of undetectable minimal…”
Get full text

Zanubrutinib, Obinutuzumab, and Venetoclax in Chronic Lymphocytic Leukemia: Early MRD Kinetics Define a High-Risk Patient Cohort with Delayed Bone Marrow Undetectable MRD and Earlier Post-Treatment MRD Recurrence by Soumerai, Jacob D., Mato, Anthony R., Dogan, Ahmet, Seshan, Venkatraman, Joffe, Erel, Flaherty, Kelsey, Carter, Jason, Hochberg, Ephraim P, Barnes, Jeffrey A, Hamilton, Audrey, Abramson, Jeremy S., Batlevi, Connie Lee, Matasar, Matthew J., Noy, Ariela, Owens, Colette, Palomba, M. Lia, Kumar, Anita, Takvorian, Tak, Ni, Ai, Choma, Morgan, Friedman, Chaya, Chadha, Puja, Simkins, Elizabeth, Ruiters, Jade, Sechio, Sidney, Portman, Daneal, Nolet, Natascha, Mahajan, Neena, Martignetti, Rosalba, Mi, Joanna, Scorsune, Krista J, Lynch, Julia M, McGree, Brianne, Hughes, Stephanie Y, Grieve, Clare, Roeker, Lindsey E., Thompson, Meghan C., Johnson, P. Connor, Roshal, Mikhail, Huang, Jane, Biondo, Juliana M.L., Wu, Jenny Qun, Jacob, Allison P., Abdel-Wahab, Omar, Zelenetz, Andrew D.

“…Background: Venetoclax (Ven; BH3 mimetic) and Obinutuzumab (O; CD20 antibody) is an approved, fixed-duration regimen (one year) that induces undetectable…”
Get full text

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial by Kater, Arnon P, Wu, Jenny Qun, Dubois, Julie, Bolen, Christopher R, Assaf, Zoe J, Hillmen, Peter, Eichhorst, Barbara F., Eldering, Eric F, Kipps, Thomas J., Langerak, Anton W, Mellink, Clemens, Van Der Kevie-Kersemaekers, Anne-Marie, Owen, Carolyn, Chyla, Brenda J, Punnoose, Elizabeth A, Wang, Jue, Lefebure, Marcus, Boyer, Michelle, Humphrey, Kathryn, Jiang, Yanwen, Seymour, John F.

“…The first two authors contributed equally. Introduction: VenR (2 years of Ven, plus R during the first 6 months) improved progression-free/overall survival…”
Get full text

High, durable minimal residual disease negativity (MRD–) with venetoclax + rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study by Hillmen, Peter, Kater, Arnon P., Seymour, John Francis, Langerak, Anton W, Eichhorst, Barbara, Owen, Carolyn, Assouline, Sarit E., Janssens, Ann, Marlton, Paula, Badoux, Xavier C., Mous, Rogier, Chyla, Brenda, Humerickhouse, Rod, Boyer, Michelle, Humphrey, Kathryn, Jiang, Yanwen, Punnoose, Elizabeth, Wang, Jue, Wu, Qun Jenny, Mobasher, Mehrdad

“…Abstract only…”
Get full text